Nyxoah Aktie
WKN DE: A2QCWK / ISIN: BE0974358906
12.04.2024 03:07:54
|
Nyxoah Appoints Maurits Boon As Chief Medical Officer
(RTTNews) - Nyxoah SA (NYXH) said that it appointed Maurits Boon as Chief Medical Officer.
Boon joins Nyxoah from the Thomas Jefferson University, where he will continue part time as a professor and Vice Chairman, Education. He is dual board-certified in otolaryngology - head and neck surgery, as well as sleep medicine.
Boon is one of two sleep surgeons with Jefferson Health to pioneer the use of hypoglossal nerve stimulation therapy. He has lectured worldwide on obstructive sleep apnea, has numerous publications and is co-editor of the first book on hypoglossal nerve stimulation therapy.

Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Nyxoah S.A. Registered Shsmehr Nachrichten
15.09.25 |
EQS-News: Nyxoah Files Patent Infringement Lawsuit Against Inspire Medical Systems, Inc. (EQS Group) | |
15.09.25 |
EQS-News: Nyxoah reicht Klage wegen Patentverletzung gegen Inspire Medical Systems, Inc. ein (EQS Group) | |
18.08.25 |
EQS-News: Nyxoah Reports Second Quarter Financial and Operating Results (EQS Group) | |
18.08.25 |
EQS-News: Nyxoah gibt Finanzergebnisse und operatives Update für das zweite Quartal bekannt (EQS Group) | |
17.08.25 |
Ausblick: Nyxoah präsentiert Quartalsergebnisse (finanzen.net) | |
11.08.25 |
EQS-News: Nyxoah Announces Preliminary Results for the Second Quarter of 2025 (EQS Group) | |
11.08.25 |
EQS-News: Nyxoah gibt vorläufige Finanzergebnisse für das zweite Quartal 2025 bekannt (EQS Group) | |
08.08.25 |
EQS-News: Nyxoah Receives Approval from FDA for Genio® System for the Treatment of Obstructive Sleep Apnea (EQS Group) |
Analysen zu Nyxoah S.A. Registered Shsmehr Analysen
Aktien in diesem Artikel
Nyxoah S.A. Registered Shs | 3,72 | -7,13% |
|